Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Omeros Corporation. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Omeros Corporation (“Omeros” or “the Company”) (NASDAQ: OMER). Investors who purchased Omeros securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Omeros has violated federal securities laws.
Omeros Investigation Details
On June 26, 2026, Omeros issued a press release “announc[ing] . . . an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).” Specifically, the press release disclosed that “[f]ollowing an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA.”
Following this news, Omeros’s stock price fell $2.05 per share, or 19.12%, to close at $8.67 per share on June 26, 2026.
What’s Next for Omeros Investors?
If you are aware of any facts relating to this investigation or purchased Omeros securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
OMER — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”